Cleared Traditional

K092736 - EUROIMMUN ANTI-M2-3E ELISA (IGG)

K092736 is the FDA 510(k) clearance for EUROIMMUN ANTI-M2-3E ELISA (IGG) by Euroimmun Us, Inc.. It is a Class 2 Immunology device (product code DBM) cleared through the Traditional 510(k) pathway after a 363-day FDA review.

K092736 · Euroimmun Us, Inc. · Immunology device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Sep 2010
Decision
363d
Days
Class 2
Risk

K092736 is an FDA 510(k) clearance for the EUROIMMUN ANTI-M2-3E ELISA (IGG). Classified as Antimitochondrial Antibody, Indirect Immunofluorescent, Antigen, Control (product code DBM), Class II - Special Controls.

Submitted by Euroimmun Us, Inc. (Morristown, US). The FDA issued a Cleared decision on September 2, 2010 after a review of 363 days - an unusually long review period, suggesting complex equivalence evaluation.

This device falls under the Immunology FDA review panel, regulated under 21 CFR 866.5090 - the FDA immunology device framework. The Traditional 510(k) pathway establishes clearance through substantial equivalence to a legally marketed predicate device, without requiring clinical trial data.

Device pattern: Standard predicate-based submission. Elevated predicate reliance profile. This clearance follows a standard predicate-based equivalence path within the Immunology review framework, consistent with the majority of Class II 510(k) submissions.

View all Euroimmun Us, Inc. devices

Submission Details

510(k) Number K092736 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received September 04, 2009
Decision Date September 02, 2010
Days to Decision 363 days
Submission Type Traditional
Review Panel Immunology (IM)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Regulatory Context
Review time vs. panel average
259d slower than avg
Panel avg: 104d · This submission: 363d
Pathway characteristics
Predicate-based equivalence. No clinical trials required.

Device Classification

Product Code DBM Antimitochondrial Antibody, Indirect Immunofluorescent, Antigen, Control
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 866.5090
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Immunology devices follow this clearance model.

Regulatory Peers - DBM Antimitochondrial Antibody, Indirect Immunofluorescent, Antigen, Control

All 15
Devices cleared under the same product code (DBM) and FDA review panel - the closest regulatory comparables to K092736.
EliA M2 Immunoassay
K181556 · Phadia AB · Jul 2018
QUANTA Flash M2 (MIT3), QUANTA Flash M2 (MIT3) Calibrators, QUANTA Flash M2 (MIT3) Controls
K163525 · Inova Diagnostics, Inc. · Sep 2017
ImmuLisa Enhanced AMA IgG Antibody ELISA
K163133 · Immco Diagnostics, Inc. · Aug 2017
QUANTA LITE M2 EP (MIT3) ELISA
K052262 · Inova Diagnostics, Inc. · Oct 2005
BINDAZYME ANTI-MITOCHONDRIA M2 IGGAM EIA KIT
K030238 · The Binding Site, Ltd. · Mar 2003
ENZYMATIC MITOCHONDRIAL ANTIBODY (M2) REAGENT
K982121 · Trace Scientific , Ltd. · Sep 1998